Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.

British journal of clinical pharmacology - 1 Nov 2006

Zhang Wei, He Yi-Jing, Han Chun-Ting, Liu Zhao-Qian, Li Qing, Fan Lan, Tan Zhi-Rong, Zhang Wei-Xia, Yu Bang-Ning, Wang Dan, Hu Dong-Li, Zhou Hong-Hao

Abstract excerpt

AIMS: Nateglinide is a meglitinide analogue with antidiabetic action. A recent study showed that SLCO1B1 (which codes the OATP1B1 gene, also known as OATP-C, OATP2) is a major determinant which markedly affects the pharmacokinetics of repaglinide. Our objective was to assess the association betwe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclohexanes
Share to Diabetes Mellitus
Share to Hypoglycemic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver-Specific Organic Anion Transporter 1

Share to Organic Anion Transporters

Share to Phenylalanine

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 16796707
DOI: 10.1111/j.1365-2125.2006.02686.x
PMCID: PMC1885174

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-16796707-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.PMID 16796707Read ↗

Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.Semantic proximity Read ↗

SLCO1B1 polymorphism and oral antidiabetic drugs.Semantic proximity Read ↗

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.Semantic proximity Read ↗

Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.Semantic proximity Read ↗

The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.Semantic proximity Read ↗

Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans.Semantic proximity Read ↗

No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.Semantic proximity Read ↗

Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.Semantic proximity Read ↗

Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.Semantic proximity Read ↗

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.Semantic proximity Read ↗

Effect of SLC22A1 polymorphism on the pharmacokinetics of proguanil in Korean: A semi-physiologic population pharmacokinetic approach.Semantic proximity Read ↗

Effects of two functionally important SLCO1B1 gene polymorphisms on pharmacokinetics of atorvastatin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.